---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-01-18T20:47:00.561191'
end_time: '2026-01-18T20:54:50.460655'
duration_seconds: 469.9
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: TP53
  gene_symbol: TP53
  uniprot_accession: P04637
  protein_description: 'RecName: Full=Cellular tumor antigen p53; AltName: Full=Antigen
    NY-CO-13; AltName: Full=Phosphoprotein p53; AltName: Full=Tumor suppressor p53;'
  gene_info: Name=TP53; Synonyms=P53;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the p53 family. .
  protein_domains: p53-like_TF_DNA-bd_sf. (IPR008967); p53/RUNT-type_TF_DNA-bd_sf.
    (IPR012346); p53_DNA-bd. (IPR011615); p53_TAD2. (IPR040926); p53_tetramer_sf.
    (IPR036674)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 22
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P04637
- **Protein Description:** RecName: Full=Cellular tumor antigen p53; AltName: Full=Antigen NY-CO-13; AltName: Full=Phosphoprotein p53; AltName: Full=Tumor suppressor p53;
- **Gene Information:** Name=TP53; Synonyms=P53;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the p53 family. .
- **Key Domains:** p53-like_TF_DNA-bd_sf. (IPR008967); p53/RUNT-type_TF_DNA-bd_sf. (IPR012346); p53_DNA-bd. (IPR011615); p53_TAD2. (IPR040926); p53_tetramer_sf. (IPR036674)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "TP53" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'TP53' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **TP53** (gene ID: TP53, UniProt: P04637) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P04637
- **Protein Description:** RecName: Full=Cellular tumor antigen p53; AltName: Full=Antigen NY-CO-13; AltName: Full=Phosphoprotein p53; AltName: Full=Tumor suppressor p53;
- **Gene Information:** Name=TP53; Synonyms=P53;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the p53 family. .
- **Key Domains:** p53-like_TF_DNA-bd_sf. (IPR008967); p53/RUNT-type_TF_DNA-bd_sf. (IPR012346); p53_DNA-bd. (IPR011615); p53_TAD2. (IPR040926); p53_tetramer_sf. (IPR036674)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "TP53" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'TP53' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **TP53** (gene ID: TP53, UniProt: P04637) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan (high-level)
- Verified the exact identity of the human target (TP53; UniProt P04637) and its domain architecture and quaternary structure, ensuring no symbol ambiguity. Built a concise verification artifact for reuse. (See embedded artifact.)
- Prioritized 2023–2024 authoritative sources (reviews and recent primary reports) to synthesize: (1) current concepts/definitions; (2) recent developments; (3) current applications/implementations; (4) expert opinions; (5) recent statistics/data.
- Focused on precise functional roles, subcellular localization, and pathway-level mechanisms (regulation by MDM2/MDM4; DNA damage response; apoptosis; ferroptosis; chromatin-level control), and on translational advances (MDM2 inhibitors; mutant-p53 reactivation strategies).

Identity verification (mandatory steps)
> Verified identity: TP53 encodes cellular tumor antigen p53 in Homo sapiens; member of the p53 family (p53/p63/p73).
> Domain architecture: N-terminal transactivation domains (TAD1, TAD2), proline-rich region, central DNA-binding domain (DBD), tetramerization/oligomerization domain, and C-terminal regulatory domain.
> Function and quaternary structure: p53 is a sequence-specific DNA-binding transcription factor that functions as an active homo-tetramer (a dimer-of-dimers) for DNA binding and transcriptional regulation. (thayer2024navigatingthecomplexity pages 1-2, ianni2023structuralassessmentof pages 1-2, liu2024understandingthecomplexity pages 1-3)


*Blockquote: Concise verification of human TP53 (UniProt P04637) confirming organism, family membership, domain architecture, transcription-factor function, and tetrameric quaternary state, with supporting citations.*

Comprehensive research report

1) Key concepts and definitions with current understanding
- Gene/protein identity and family: Human TP53 encodes the cellular tumor antigen p53, a member of the p53 family (p53, p63, p73). p53 is a 393‑aa transcription factor with defined modular domains: N‑terminal transactivation domains (TAD1/TAD2), a proline‑rich region, a central sequence‑specific DNA‑binding domain (DBD), a tetramerization/oligomerization domain, and a C‑terminal regulatory domain. Functional p53 binds p53 response elements as a homo‑tetramer (dimer‑of‑dimers) to regulate target genes in response to stress (DNA damage, oncogenic signaling, hypoxia, nutrient stress) (Biophysical Reviews, Jul 2024; DOI: 10.1007/s12551-024-01207-4; Ianni et al., 2023; Cancer Cell, Jun 2024; DOI: 10.1016/j.ccell.2024.04.009) (thayer2024navigatingthecomplexity pages 1-2, ianni2023structuralassessmentof pages 1-2, liu2024understandingthecomplexity pages 1-3).
- Canonical roles: p53 coordinates cell‑cycle arrest (e.g., CDKN1A/p21), apoptosis (e.g., PUMA, NOXA), senescence, DNA repair, metabolic rewiring, and other stress responses as a sequence‑specific transcription factor; zinc coordination and structured DBD enable sequence recognition, while disordered termini integrate regulatory inputs (Critical Reviews in Biochemistry and Molecular Biology, Mar 2024; DOI: 10.1080/10409238.2024.2344465; Cancer Cell, Jun 2024) (indeglia2024elucidatingthechain pages 1-3, liu2024understandingthecomplexity pages 1-3).
- Domain architecture and quaternary organization details: Residue‑mapped regions for human p53 include TAD (~1–62; sub‑segmented into TAD1/TAD2), proline‑rich (~63–100), DBD (~102–292), tetramerization (~320–360), and C‑terminal regulatory region (~361–393). The oligomerization domain drives dimerization and tetramerization, which is essential for high‑affinity DNA binding and full transcriptional activity (Biophysical Reviews, Jul 2024; Ianni et al., 2023) (thayer2024navigatingthecomplexity pages 1-2, ianni2023structuralassessmentof pages 1-2).

2) Recent developments and latest research (2023–2024 priority)
- Updated integrative view of p53 biology: Recent synthesis highlights layers of regulation (post‑translational modifications, cofactor interactions, chromatin context), and expands p53’s roles in metabolism and non‑apoptotic cell death (e.g., ferroptosis) (Cancer Cell, Jun 2024; DOI: 10.1016/j.ccell.2024.04.009) (liu2024understandingthecomplexity pages 1-3).
- Drugging p53 (state-of-the-art): A 2023 Nature Reviews Drug Discovery analysis re‑evaluates strategies: (i) protecting wild‑type p53 from MDM2/MDM4 (antagonists, degraders), (ii) restoring mutant‑p53 function (mutation‑selective or broader reactivators), and (iii) gene therapy and immunotherapy concepts. It emphasizes ongoing clinical activity but absence of FDA/EMA approvals to date (Nature Reviews Drug Discovery, Oct 2023; DOI: 10.1038/s41573-022-00571-8) (hassin2023druggingp53in pages 1-2).
- Ferroptosis and p53: Contemporary reviews place p53 as a context‑dependent regulator of ferroptosis via transcriptional control (e.g., SLC7A11 and other metabolic nodes), linking redox and lipid‑peroxide homeostasis to tumor suppression (Cancer Cell, Jun 2024) (liu2024understandingthecomplexity pages 1-3).
- 3D genome/condensates and chromatin regulation: Emerging work indicates p53 activation is intertwined with chromatin architecture and can rapidly re‑configure genome topology, while intrinsic disorder and multivalent interactions underlie dynamic regulation; these insights refine how p53 selects targets under distinct cellular contexts (PhD thesis/ArXiv 2024; DOI: 10.5821/dissertation-2117-422069; summary perspective) (pasadas2024exploringtheimpact pages 42-46).
- p53 targetome refinements: Updated curation of p53 target genes underscores both canonical targets (p21, PUMA) and additional stress‑integration targets that feed back on proteostasis and RNA biology (Critical Reviews in Biochemistry and Molecular Biology, Mar 2024) (indeglia2024elucidatingthechain pages 1-3).

3) Current applications and real-world implementations
- MDM2 antagonists in the clinic: Recent reviews summarize next‑generation MDM2 inhibitors including brigimadlin (BI 907828), siremadlin (HDM201), and milademetan (RAIN‑32). These agents stabilize wild‑type p53 by blocking MDM2‑p53, with most advanced programs reporting early‑phase efficacy signals alongside class‑typical hematologic toxicities; combination strategies are prioritized clinically to improve depth/durability of responses (Biomarker Research, Mar 2024; Nature Reviews Drug Discovery, Oct 2023) (zawacka2024p53biologyand pages 16-16, hassin2023druggingp53in pages 1-2).
- Disease‑specific deployment: In biliary tract cancers, comprehensive 2024 review highlights MDM2 amplification (~5–8%) as a biomarker and describes brigimadlin as a potent MDM2–p53 antagonist entering potential registrational testing, reinforcing the role of broad molecular profiling to capture targetable p53‑pathway lesions (Future Oncology, May 2024; DOI: 10.1080/14796694.2024.2340959) (shroff2024treatmentoptionsfor pages 1-2).
- Hematologic malignancies: 2024 synthesis for MDS/AML positions TP53‑mutant disease as a distinct high‑risk entity with inferior responses to chemotherapy, HMA, and venetoclax regimens; efforts include p53/MDM2/MDM4 modulation (for wild‑type settings) and mutant‑p53 reactivation/degradation strategies (Biomarker Research, Mar 2024) (zawacka2024p53biologyand pages 16-16).

4) Expert opinions and analysis from authoritative sources
- Oren & Hassin (2023) — strategic perspective: p53’s “undruggable” label is being challenged by (i) refined protein–protein interaction inhibitors (MDM2/MDM4), (ii) mutant‑selective reactivators (e.g., allele‑tailored agents), and (iii) gene therapy/immunotherapy. The review calls for biomarker‑guided patient selection and combination regimens to overcome resistance and on‑target hematologic liabilities (Nature Reviews Drug Discovery, Oct 2023; https://doi.org/10.1038/s41573-022-00571-8) (hassin2023druggingp53in pages 1-2).
- Liu et al. (2024) — systems view: p53’s tumor suppression reflects integrated transcriptional control layered onto chromatin context and stress signaling; expanding roles in metabolism and ferroptosis offer therapeutic entry points but demand careful context‑specific strategies (Cancer Cell, Jun 2024; https://doi.org/10.1016/j.ccell.2024.04.009) (liu2024understandingthecomplexity pages 1-3).
- Zawacka (2024) — hematology practice: TP53‑mutated myeloid neoplasms have the poorest prognosis; wild‑type p53 reactivation (MDM2/MDM4 axis) and mutant‑p53 reactivation/degradation remain the two major translational directions, with a need for better allelic‑status assessment (Biomarker Research, Mar 2024; https://doi.org/10.1186/s40364-024-00579-9) (zawacka2024p53biologyand pages 16-16).

5) Recent statistics and data (2023–2024 sources prioritized)
- Prevalence across cancers: Authoritative reviews reaffirm TP53 as the most frequently impaired tumor suppressor; approximately half of human cancers harbor TP53 alterations, with context‑dependent patterns of DNA‑contact vs conformational (structural) mutants and gain‑of‑function properties (Nature Reviews Drug Discovery, Oct 2023; Cancer Cell, Jun 2024) (hassin2023druggingp53in pages 1-2, liu2024understandingthecomplexity pages 1-3).
- Myeloid malignancies and precursors: TP53 mutations occur in ~5–13% of de novo MDS/AML; therapy‑related myeloid neoplasms have higher TP53 mutation rates (20–40%). Clonal hematopoiesis with TP53 mutations occurs in ~2–6% of cancer patients; CH progression is ~0.5–1%/year. Biallelic TP53 generally portends median survival under one year in AML/MDS (Biomarker Research, Mar 2024; https://doi.org/10.1186/s40364-024-00579-9) (zawacka2024p53biologyand pages 16-16).
- Biliary tract cancer biomarker: MDM2 amplification in ~5–8% of BTC tumor samples supports clinical exploration of MDM2 inhibition (Future Oncology, May 2024; https://doi.org/10.1080/14796694.2024.2340959) (shroff2024treatmentoptionsfor pages 1-2).

Detailed functional roles, localization, and pathway placement
- Molecular function: p53 is a zinc‑coordinated, sequence‑specific transcription factor that binds to p53 response elements as a homo‑tetramer to activate/repress gene networks controlling cell cycle, apoptosis, senescence, DNA repair, and metabolism (Critical Reviews in Biochemistry and Molecular Biology, 2024; Biophysical Reviews, 2024; Cancer Cell, 2024) (indeglia2024elucidatingthechain pages 1-3, thayer2024navigatingthecomplexity pages 1-2, liu2024understandingthecomplexity pages 1-3).
- Subcellular localization and dynamics: p53 accumulates in the nucleus upon activation to regulate chromatin‑embedded targets; its intrinsically disordered N‑ and C‑terminal regions, together with the DBD and oligomerization domain, enable dynamic assembly and genome engagement (Ianni et al., 2023; Cancer Cell, 2024; ArXiv, 2024) (ianni2023structuralassessmentof pages 1-2, liu2024understandingthecomplexity pages 1-3, pasadas2024exploringtheimpact pages 42-46).
- Pathway positioning: In homeostasis, MDM2 (and MDM4) constrain p53 levels via ubiquitin‑proteasome turnover. Upon stress (e.g., ATM/ATR signaling), p53 stabilization and tetramer formation drive transcription of target genes that implement arrest, repair, death, and metabolic rewiring. Expanded areas include ferroptosis control (e.g., SLC7A11 axis) and broader immuno‑metabolic interfaces (Cancer Cell, 2024; Nature Reviews Drug Discovery, 2023) (liu2024understandingthecomplexity pages 1-3, hassin2023druggingp53in pages 1-2).

Translational landscape: therapeutic classes and examples
- Wild‑type p53 activation: MDM2 antagonists (e.g., brigimadlin/BI 907828; siremadlin/HDM201; milademetan/RAIN‑32) have shown antitumor activity in early trials and active development in combinations to enhance apoptosis while mitigating class toxicities (Biomarker Research, Mar 2024; Nature Reviews Drug Discovery, Oct 2023) (zawacka2024p53biologyand pages 16-16, hassin2023druggingp53in pages 1-2).
- Mutant‑p53 reactivation: Programs remain active but are heterogeneous in mechanism and clinical maturity. APR‑246 (eprenetapopt) illustrates a leading approach tested in AML/MDS and ovarian cancer settings; future efforts emphasize mutation‑selective agents (e.g., Y220C‑specific strategies) and degradation‑based tactics (Nature Reviews Drug Discovery, Oct 2023) (hassin2023druggingp53in pages 1-2).
- Indications emphasizing biomarker testing: 2024 BTC synthesis recommends comprehensive profiling to identify MDM2 amplification and other targetable alterations, guiding enrollment in MDM2 inhibitor studies (Future Oncology, May 2024) (shroff2024treatmentoptionsfor pages 1-2).

Caveats, open questions, and best practices
- Context‑dependence: p53 outputs depend on DNA‑binding motif features, chromatin state, cofactor availability, and stress signaling; thus, target‑gene repertoires and cell‑fate choices vary across tissues and lineages (Cancer Cell, Jun 2024) (liu2024understandingthecomplexity pages 1-3).
- Therapeutic liabilities: MDM2 inhibitors frequently produce hematologic toxicities; optimizing dosing schedules and combination partners is central to translation (Nature Reviews Drug Discovery, Oct 2023) (hassin2023druggingp53in pages 1-2).
- Mutation tailoring: The heterogeneity of TP53 mutations and gain‑of‑function phenotypes argues for mutation‑informed selection and pharmacology (Nature Reviews Drug Discovery, Oct 2023) (hassin2023druggingp53in pages 1-2).

References (URLs and dates)
- Thayer KM et al. Biophysical Reviews. Published online 11 Jul 2024. Navigating the complexity of p53‑DNA binding. https://doi.org/10.1007/s12551-024-01207-4 (thayer2024navigatingthecomplexity pages 1-2)
- Ianni A et al. 2023. Structural assessment of full‑length wild‑type p53 (integrative modeling). https://doi.org/10.25673/109567 (ianni2023structuralassessmentof pages 1-2)
- Liu Y et al. Cancer Cell. Jun 2024. Understanding the complexity of p53 in a new era of tumor suppression. https://doi.org/10.1016/j.ccell.2024.04.009 (liu2024understandingthecomplexity pages 1-3)
- Indeglia A, Murphy ME. Critical Reviews in Biochemistry and Molecular Biology. Mar 2024. Critical p53 target genes for tumor suppression. https://doi.org/10.1080/10409238.2024.2344465 (indeglia2024elucidatingthechain pages 1-3)
- Hassin O, Oren M. Nature Reviews Drug Discovery. Oct 2023. Drugging p53 in cancer. https://doi.org/10.1038/s41573-022-00571-8 (hassin2023druggingp53in pages 1-2)
- Zawacka JE. Biomarker Research. Mar 2024. p53 biology and reactivation in MDS/AML. https://doi.org/10.1186/s40364-024-00579-9 (zawacka2024p53biologyand pages 16-16)
- Shroff RT, Bachini M. Future Oncology. May 2024. BTC targets and MDM2 amplification; brigimadlin development. https://doi.org/10.1080/14796694.2024.2340959 (shroff2024treatmentoptionsfor pages 1-2)
- Pasadas MC. 2024 (ArXiv/Thesis). p53 activation and spatio‑temporal genome topology. https://doi.org/10.5821/dissertation-2117-422069 (pasadas2024exploringtheimpact pages 42-46)

Conclusion
Human TP53 (UniProt P04637) encodes the p53 tumor suppressor, a tetrameric sequence‑specific transcription factor with well‑defined domains that integrate stress signals to direct cell fate. Recent work (2023–2024) consolidates p53’s central roles while expanding mechanisms in metabolism and ferroptosis, chromatin/3D‑genome coupling, and translational strategies. Clinically, MDM2 inhibitors (e.g., brigimadlin) exemplify progress in wild‑type p53 activation, while mutant‑p53 reactivation remains an active frontier. Effective translation hinges on biomarker‑guided selection, optimized combinations, and attention to context‑dependent p53 biology (thayer2024navigatingthecomplexity pages 1-2, ianni2023structuralassessmentof pages 1-2, liu2024understandingthecomplexity pages 1-3, hassin2023druggingp53in pages 1-2, zawacka2024p53biologyand pages 16-16, shroff2024treatmentoptionsfor pages 1-2).

References

1. (thayer2024navigatingthecomplexity pages 1-2): Kelly M. Thayer, Sean Stetson, Fernando Caballero, Christopher Chiu, and In Sub Mark Han. Navigating the complexity of p53-dna binding: implications for cancer therapy. Biophysical Reviews, 16:479-496, Jul 2024. URL: https://doi.org/10.1007/s12551-024-01207-4, doi:10.1007/s12551-024-01207-4. This article has 11 citations and is from a peer-reviewed journal.

2. (ianni2023structuralassessmentof pages 1-2): Alessio Ianni, Christian Tüting, Marc Kipping, Christian H. Ihling, Janett Köppen, Claudio Iacobucci, Christian Arlt, Panagiotis L. Kastritis, and Andrea Sinz. Structural assessment of the full-length wild-type tumor suppressor protein p53 by mass spectrometry-guided computational modeling. Text, Jan 2023. URL: https://doi.org/10.25673/109567, doi:10.25673/109567. This article has 8 citations and is from a peer-reviewed journal.

3. (liu2024understandingthecomplexity pages 1-3): Yanqing Liu, Zhenyi Su, Omid Tavana, and Wei Gu. Understanding the complexity of p53 in a new era of tumor suppression. Cancer Cell, 42:946-967, Jun 2024. URL: https://doi.org/10.1016/j.ccell.2024.04.009, doi:10.1016/j.ccell.2024.04.009. This article has 361 citations and is from a highest quality peer-reviewed journal.

4. (indeglia2024elucidatingthechain pages 1-3): Alexandra Indeglia and Maureen E. Murphy. Elucidating the chain of command: our current understanding of critical target genes for p53-mediated tumor suppression. Critical Reviews in Biochemistry and Molecular Biology, 59:128-138, Mar 2024. URL: https://doi.org/10.1080/10409238.2024.2344465, doi:10.1080/10409238.2024.2344465. This article has 18 citations and is from a peer-reviewed journal.

5. (hassin2023druggingp53in pages 1-2): Ori Hassin and Moshe Oren. Drugging p53 in cancer: one protein, many targets. Nature Reviews. Drug Discovery, 22:127-144, Oct 2023. URL: https://doi.org/10.1038/s41573-022-00571-8, doi:10.1038/s41573-022-00571-8. This article has 677 citations.

6. (pasadas2024exploringtheimpact pages 42-46): Mónica Cabrera Pasadas. Exploring the impact of p53 activation on spatio-temporal genome topology. ArXiv, 2024. URL: https://doi.org/10.5821/dissertation-2117-422069, doi:10.5821/dissertation-2117-422069. This article has 0 citations.

7. (zawacka2024p53biologyand pages 16-16): Joanna E. Zawacka. P53 biology and reactivation for improved therapy in mds and aml. Biomarker Research, Mar 2024. URL: https://doi.org/10.1186/s40364-024-00579-9, doi:10.1186/s40364-024-00579-9. This article has 18 citations and is from a peer-reviewed journal.

8. (shroff2024treatmentoptionsfor pages 1-2): Rachna T Shroff and Melinda Bachini. Treatment options for biliary tract cancer: unmet needs, new targets and opportunities from both physicians' and patients' perspectives. Future Oncology, 20:1435-1450, May 2024. URL: https://doi.org/10.1080/14796694.2024.2340959, doi:10.1080/14796694.2024.2340959. This article has 8 citations and is from a peer-reviewed journal.

## Citations

1. liu2024understandingthecomplexity pages 1-3
2. pasadas2024exploringtheimpact pages 42-46
3. indeglia2024elucidatingthechain pages 1-3
4. shroff2024treatmentoptionsfor pages 1-2
5. thayer2024navigatingthecomplexity pages 1-2
6. ianni2023structuralassessmentof pages 1-2
7. https://doi.org/10.1038/s41573-022-00571-8
8. https://doi.org/10.1016/j.ccell.2024.04.009
9. https://doi.org/10.1186/s40364-024-00579-9
10. https://doi.org/10.1080/14796694.2024.2340959
11. https://doi.org/10.1007/s12551-024-01207-4
12. https://doi.org/10.25673/109567
13. https://doi.org/10.1080/10409238.2024.2344465
14. https://doi.org/10.5821/dissertation-2117-422069
15. https://doi.org/10.1007/s12551-024-01207-4,
16. https://doi.org/10.25673/109567,
17. https://doi.org/10.1016/j.ccell.2024.04.009,
18. https://doi.org/10.1080/10409238.2024.2344465,
19. https://doi.org/10.1038/s41573-022-00571-8,
20. https://doi.org/10.5821/dissertation-2117-422069,
21. https://doi.org/10.1186/s40364-024-00579-9,
22. https://doi.org/10.1080/14796694.2024.2340959,